RenovoRx (RNXT) Convertible Debt (2021)
RenovoRx (RNXT) posted Convertible Debt of $5.3 million for Q4 2021, little changed sequentially from $5.3 million in Q3 2021.
RenovoRx (RNXT) Convertible Debt (2021) Analysis & Trends
RenovoRx has reported Convertible Debt for 1 years, with the latest figure at $5.3 million in Q4 2021.
- Quarterly Convertible Debt changed N/A year-over-year to $5.3 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.3 million (changed N/A YoY) and the FY2021 annual result came in at $5.3 million, changed N/A from the prior year.
- Convertible Debt was little changed at $5.3 million in Q4 2021 per RNXT's latest filing, from $5.3 million in the prior quarter.
- Over five years, Convertible Debt peaked at $5.3 million in Q3 2021 and troughed at $5.3 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | RenovoRx | 61.49 Mn | 61.49 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.30 Mn |
| Sep 30, 2021 | 5.30 Mn |